{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:29:08Z","timestamp":1790213348968,"version":"4.1.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JASN"],"published-print":{"date-parts":[[2019,7]]},"abstract":"\n Significance Statement<\/jats:title>\n Although angiotensin-converting enzyme (ACE) inhibitor and angiotensin II receptor blocker (ARB) medications are mainstays of treatment in CKD, the frequency of ACE\/ARB use has not been well characterized in this population. Nationally representative data from 1999 to 2014 showed that overall ACE\/ARB use during this period was only 34.9% among those with CKD; use rose significantly with time (from 25.5% in 1999\u20132002 to 40.1% in 2011\u20132014) but seemed to level off after the early 2000s, a trend similarly observed in multiple CKD subgroups. Overall, regardless of era, ACE\/ARB use in CKD was the exception unless concomitant illnesses, like diabetes mellitus or cardiac disease, were present. This suggests that a significant opportunity exists for improvement in the care in community-based CKD.<\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n Although hypertension is common in CKD and evidence-based treatment of hypertension has changed considerably, contemporary and nationally representative information about use of angiotensin-converting enzyme (ACEs) inhibitors or angiotensin II receptor blockers (ARBs) in CKD is lacking.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n We examined ACE\/ARB trends from 1999 to 2014 among 38,885 adult National Health and Nutrition Examination Survey participants with creatinine-based eGFR<60 ml\/min per 1.73 m\n 2<\/jats:sup>\n or urinary albumin-to-creatinine ratio \u226530 mg\/g.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 7085 participants with CKD, 34.9% used an ACE\/ARB. Across four eras studied, rates of use rose significantly (rates were 25.5% in 1999\u20132002, 33.3% in 2003\u20132006, 39.0% in 2007\u20132010, and 40.1% in 2011\u20132014) but appeared to plateau after 2003. Among those with CKD, use was significantly greater among non-Hispanic white and black individuals (36.1% and 38.2%, respectively) and lower among Hispanic individuals (26.7%) and other races\/ethnicities (29.3%). In age-, sex-, and race\/ethnicity-adjusted models, ACE\/ARB use was significantly associated with era (adjusted odds ratios [aOR], 1.41; 95% confidence interval [95% CI], 1.14 to 1.74 for 2003\u20132006, 1.84; 95% CI, 1.48 to 2.28 for 2007\u20132010, and 2.02; 95% CI, 1.61 to 2.53 for 2011\u20132014 versus 1999\u20132002); it also was significantly associated with non-Hispanic black versus non-Hispanic white race\/ethnicity (aOR, 1.40; 95% CI, 1.19 to 1.66). Other multivariate associations included older age, men, elevated BMI, diabetes mellitus, treated hypertension, cardiac failure, myocardial infarction, health insurance, and receiving medical care within the prior year.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Rates of ACE\/ARB use increased in the early 2000s among United States adults with CKD, but for unclear reasons, use appeared to plateau in the ensuing decade. Research examining barriers to care and other factors is needed.<\/jats:p>\n <\/jats:sec>","DOI":"10.1681\/asn.2018100971","type":"journal-article","created":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T13:39:08Z","timestamp":1559741948000},"page":"1314-1321","source":"Crossref","is-referenced-by-count":89,"title":["Trends in Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use among Those with Impaired Kidney Function in the United States"],"prefix":"10.1681","volume":"30","author":[{"given":"Daniel P.","family":"Murphy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Drawz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert N.","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,6,5]]},"reference":[{"key":"B1-20230819","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies.","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"B2-20230819","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","article-title":"Blood pressure and incidence of twelve cardiovascular diseases: Lifetime risks, healthy life-years lost, and age-specific associations in 1\u00b725 million people.","volume":"383","author":"Rapsomaniki","year":"2014","journal-title":"Lancet"},{"key":"B3-20230819","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1681\/ASN.2004080656","article-title":"Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the atherosclerosis risk in communities study.","volume":"16","author":"Muntner","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B4-20230819","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control.","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"B5-20230819","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: A report of the American College of Cardiology\/American heart association task force on clinical practice guidelines.","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"B6-20230819","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8).","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"B7-20230819","first-page":"337","article-title":"KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease.","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"B8-20230819","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"B9-20230819","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart outcomes prevention evaluation study investigators.","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"B10-20230819","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency.","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"},{"key":"B11-20230819","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"B12-20230819","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial.","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"B13-20230819","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"B14-20230819","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"B15-20230819","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial.","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"key":"B16-20230819","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"key":"B17-20230819","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"B18-20230819","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"B19-20230819","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"B20-20230819","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines.","volume":"127","author":"O\u2019Gara","year":"2013","journal-title":"Circulation"},{"key":"B21-20230819","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1161\/CIR.0000000000000133","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: Executive summary: A report of the American College of Cardiology\/American heart association task force on practice guidelines.","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"B22-20230819","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2015.13766","article-title":"Trends in prescription drug use among adults in the United States from 1999-2012.","volume":"314","author":"Kantor","year":"2015","journal-title":"JAMA"},{"key":"B23-20230819","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1161\/CIRCULATIONAHA.112.096156","article-title":"Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: The National Health and Nutrition Examination Survey, 2001 to 2010.","volume":"126","author":"Gu","year":"2012","journal-title":"Circulation"},{"key":"B24-20230819","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1161\/CIRCULATIONAHA.105.542290","article-title":"Antihypertensive medication use among US adults with hypertension.","volume":"113","author":"Gu","year":"2006","journal-title":"Circulation"},{"key":"B26-20230819","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B27-20230819","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1053\/j.ajkd.2007.08.020","article-title":"Calibration of serum creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988-1994, 1999-2004.","volume":"50","author":"Selvin","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"B30-20230819","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification.","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"B31-20230819","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: A position statement from kidney disease: Improving Global Outcomes (KDIGO).","volume":"67","author":"Levey","year":"2005","journal-title":"Kidney Int"},{"key":"B32-20230819","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2337\/dc09-9033","article-title":"International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes.","volume":"32","year":"2009","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"B35-20230819","first-page":"S34","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: Standards of medical care in diabetes-2019.","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"key":"B36-20230819","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2011.861","article-title":"Temporal trends in the prevalence of diabetic kidney disease in the United States.","volume":"305","author":"de Boer","year":"2011","journal-title":"JAMA"},{"key":"B37-20230819","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014.","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201907000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:22:19Z","timestamp":1786130539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201907000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,5]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2018100971","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,5]]}}}